Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
Other Sizes |
|
ln Vitro |
The enhancement of NO expression generated by Physalin A treatment was greatly decreased by Carboxy-PTIO k (200 μM; 1 hour before Physalin A; 24 hours); however, Carboxy-PTIO therapy alone did not cause any alterations [1]. μM; Physalin A 1 hour; 24 hours) decreases internal procaspase-3 and PARP caused by physalin A, impairs the expression of ICAD, and lessens nucleus DNA fragmentation [1]. Carboxy-PTIO Potassium (200 μM; Physalin A 1 hour ago) did not affect iNOS expression, but it did reverse the downregulation of mTOR and p-mTOR levels in A375-S2 cells caused by Physalin A. It also inhibited LC3 in I to LC3; 24 hr.
|
---|---|
ln Vivo |
In LPS treatment, carboxy-PTIO (intravenous; 0.056-1.70 mg/kg/min; administered for 1 hour beginning 90 minutes after LPS injection) reduces newborn rates, hypotension, and renal failure.
|
Cell Assay |
Western Blot Analysis[1]
Cell Types: A375-S2 Cell Tested Concentrations: 200 μM Incubation Duration: 1 h before conversion of physalin A; II[1]. 24-hour Experimental Results: Physalin A-induced cleavage of procaspase-3 and PARP was diminished. |
Animal Protocol |
Animal/Disease Models: SD rats [3]
Doses: 0.056-1.70 mg/kg/min Route of Administration: intravenous (iv) (iv)injection; it does not affect the parameters of normal mice [3]. 0.056-1.70 mg/kg/min; Infusion started 90 minutes after LPS injection for 1 hour and 90 minutes. Experimental Results: Through the direct scavenging effect of NO, it demonstrated effective therapeutic value in endotoxic shock. |
References |
[1]. Hao He, et al.Nitric oxide induces apoptosis and autophagy; autophagy down-regulates NO synthesis in physalin A-treated A375-S2 human melanoma cells.Food Chem Toxicol. 2014 Sep;71:128-35.
[2]. T Akaike, et al. Antagonistic action of imidazolineoxyl N-oxides against endothelium-derived relaxing factor/.NO through a radical reaction. Biochemistry. 1993 Jan 26;32(3):827-32. [3]. M Yoshid, et al. Therapeutic effects of imidazolineoxyl N-oxide against endotoxin shock through its direct nitric oxide-scavenging activity. Biochem Biophys Res Commun. 1994 Jul 29;202(2):923-30. |
Molecular Formula |
C14H16KN2O4
|
---|---|
Molecular Weight |
315.39
|
CAS # |
148819-94-7
|
Related CAS # |
Carboxy-PTIO;145757-47-7
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
CC1(C)C(C)(C)N(C(=[N+]1[O-])C2=CC=C(C=C2)C(=O)[O-])[O].[K+]
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : ~25 mg/mL (~79.27 mM)
DMSO : ~10 mg/mL (~31.71 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (158.53 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.1707 mL | 15.8534 mL | 31.7068 mL | |
5 mM | 0.6341 mL | 3.1707 mL | 6.3414 mL | |
10 mM | 0.3171 mL | 1.5853 mL | 3.1707 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.